The results of initial laboratory investigations were normal for hepatic, renal (Table) , and thyroid function but there was mild hypokalaemia for which supplementation was started with Sando-K (two tablets three times a day). Within 12 hours of starting the intravenous amiodarone the liver function tests were noticeably abnormal and he had developed signs of hepatic encephalopathy (grade 1). He became oliguric with increases in creatinine and urea. There was a neutrophil leukocytosis with appreciable derangement of the clotting times. He subsequently became thrombocytopenic with hypokalaemia and hypocalcaemia.
normal initial investigations, there was a noticeable rise in serum transaminases as well as an increase in clotting times, a decrease in renal function and a thrombocytopenia. These changes returned to normal within seven days of withdrawal of the drug without specific treatment, and the patient was later treated with oral amiodarone without any further evidence of hepatotoxicity. Intravenous amiodarone has been implicated in acute hepatic disease on four previous occasions, but it is suggested that polysorbate 80, an organic surfactant added to the intravenous infusion, is a more likely cause of this complication. Similar reactions have been described with polysorbate 80 in association with the 'E-ferol' syndrome in infants. The results of initial laboratory investigations were normal for hepatic, renal (Table) , and thyroid function but there was mild hypokalaemia for which supplementation was started with Sando-K (two tablets three times a day). Within 12 hours of starting the intravenous amiodarone the liver function tests were noticeably abnormal and he had developed signs of hepatic encephalopathy (grade 1). He became oliguric with increases in creatinine and urea. There was a neutrophil leukocytosis with appreciable derangement of the clotting times. He subsequently became thrombocytopenic with hypokalaemia and hypocalcaemia.
A toxic hepatitis was suspected and the amiodarone was stopped after 24 hours. The hepatitis and the renal failure were treated conservatively. Severe acute hepatitis immediately after intravenous amiodarone has been reported four times.' Never before, however, has oral amiodarone been reintroduced after this type of reaction. As oral amiodarone had no adverse effect on the liver function in our patient, we suggest that it may have been one of the other constituents of the intravenous solution which was responsible for the hepatotoxicity.
In order to obtain stable solutions of amiodarone for intravenous use, the drug is dissolved in a mixture of polysorbate 80 (polyoxenethylated sorbitan ester) a small amount of benzylacohol, and water. Polysorbate 80 has been implicated in the E-ferol syndrome which has been described in infants. 
